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Abstract
Loss-of-function mutations in SGCE, which encodes ε-sarcoglycan (ε-SG), cause myoclonus--
dystonia syndrome (OMIM159900, DYT11). A “major” ε-SG protein derived from CCDS5637.1 
(NM_003919.2) and a “brain-specific” protein, that includes sequence derived from alternative 
exon 11b (CCDS47642.1, NM_001099400.1), are reportedly localized in post- and pre-synaptic 
membrane fractions, respectively. Moreover, deficiency of the “brain-specific” isoform and other 
isoforms derived from exon 11b may be central to the pathogenesis of DYT11. However, no 
animal model supports this hypothesis. Gene-trapped ES cells (CMHD-GT_148G1-3, intron 9 of 
NM_011360) were used to generate a novel Sgce mouse model (C57BL/6J background) with 
markedly reduced expression of isoforms derived from exons 3′ to exon 9 of NM_011360. 
Among those brain regions analyzed in adult (2 month-old) wild-type (WT) mice, cerebellum 
showed the highest relative expression of isoforms incorporating exon 11b. Homozygotes 
(SgceGt(148G1)Cmhd/Gt(148G1)Cmhd or SgceGt/Gt) and paternal heterozygotes (Sgcem+/pGt, m-
maternal, p-paternal) showed 60 to 70% reductions in expression of total Sgce. Although 
expression of the major (NM_011360) and brain-specific (NM_001130189) isoforms was 
markedly reduced, expression of short isoforms was preserved and relatively small amounts of 
chimeric ε-SG/β-galactosidase fusion protein was produced by the Sgce gene-trap locus. 
Immunoaffinity purification followed by mass spectrometry assessments of Sgcem+/pGt mouse 
brain using pan- or brain-specific ε-SG antibodies revealed significant reductions of ε-SG and 
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other interacting sarcoglycans. Genome-wide gene-expression data using RNA derived from adult 
Sgcem+/pGt mouse cerebellum showed that the top up-regulated genes were involved in cell cycle, 
cellular development, cell death and survival, while the top down-regulated genes were associated 
with protein synthesis, cellular development, and cell death and survival. In comparison to WT 
littermates, Sgcem+/pGt mice exhibited “tiptoe” gait and stimulus-induced appendicular posturing 
between Postnatal Days 14 to 16. Abnormalities noted in older Sgcem+/pGt mice included reduced 
body weight, altered gait dynamics, and reduced open-field activity. Overt spontaneous or 
stimulus-sensitive myoclonus was not apparent on the C57BL/6J background or mixed C57BL/6J-
BALB/c and C57BL/6J-129S2 backgrounds. Our data confirm that mouse Sgce is a maternally 
imprinted gene and suggests that short Sgce isoforms may compensate, in part, for deficiency of 
major and brain-specific Sgce isoforms.
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1. Introduction
Myoclonus-dystonia syndrome is a clinically and genetically heterogeneous disorder 
characterized by myoclonic jerks affecting mainly proximal muscles of the upper 
extremities, neck and trunk. Mutations (missense, nonsense, splicing, insertions, and 
deletions) in SGCE represent a major cause of the myoclonus-dystonia syndrome (MDS, 
DYT11, OMIM-159900)(Zimprich et al., 2001, Aichhorn et al., 2006) (Asmus et al., 2005) 
and are believed to cause disease via loss-of-function mechanisms (Kinugawa et al., 2009, 
Xiao et al., 2013). The onset of the disorder is usually in the first or second decade of life. 
Females tend to have earlier onset and greater probability of leg involvement than males 
(Raymond et al., 2008). SGCE is a maternally imprinted gene and MDS is inherited in an 
autosomal dominant fashion with reduced penetrance (Zimprich et al., 2001). SGCE 
encodes the epsilon member of the sarcoglycan (SG) family (ε-SG), single pass 
transmembrane proteins that are components of the dystrophin-glycoprotein complex 
(DGC). In cardiac and skeletal muscle, the DGC connects the actin cytoskeleton to the 
extracellular matrix.
In humans and mice, SGCE/Sgce harbors several alternatively spliced exons (Fig. 1) (Yokoi 
et al., 2005, Nishiyama et al., 2004, Ritz et al., 2011). In humans, a “brain-specific” isoform 
that incorporates alternative exon 11b (CCDS47642.1, NM_001099400.1, 
NP_001123661.1) shows high expression in Purkinje cells and neurons of the cerebellar 
dentate nucleus with significantly lower levels in the globus pallidus, striatum and substantia 
nigra (Ritz et al., 2011). In mice, the “major” ε-SG protein derived from NM_011360 
(NP_035490.3) and the “brain-specific” isoform are reportedly localized in post- and pre-
synaptic membrane fractions, respectively (Nishiyama et al., 2004). Mice may also express 
another “brain-specific” isoform encoded by an elongated exon 11b (exon 11c) (Yokoi et al., 
2005). Proteins derived from transcripts containing either exon 11b or 11c encode proteins 
with C-terminal PDZ-binding motifs (Yokoi et al., 2005). Therefore, it has been suggested 
that the brain-specific isoforms may be central to the pathogenesis of MDS. However, 
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although 11b was not screened in several published cohorts, no disease-associated mutations 
in terminal exons of SGCE (exons 11, 11b and 12) have been reported in patients with MDS 
(Table 1). Furthermore, the capacity of ε-SG to tolerate deleterious variants encoded by 11b 
is difficult to estimate given that 11b was not captured in many large whole-exome 
sequencing projects (Table S1). On the other hand, there are relatively few reported 
sequence variants in the terminal exons of SGCE (Table S1) which encode the C-terminus 
PDZ-binding cytoplasmic domain of ε-SG.
Several mouse models have been used to explore the biology of ε-SG and pathobiology of 
MDS. Overexpression of wild-type (WT) ε-SG in mice resulted in substitution of ε-SG for 
α-SG in muscle DGC without overt behavioral or morphological consequences (Imamura et 
al., 2005). Paternal heterozygous null mice (Sgcem+/p−) were reported to exhibit myoclonus, 
increased slips on a beam-walking test, hyperactivity, and higher levels of striatal dopamine 
(DA) and dopamine metabolites 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic 
acid (HVA) (Yokoi et al., 2006). In contrast, mice with conditional knock-out (KO) of Sgce 
in Purkinje cells showed subtle motor learning deficits but did not exhibit myoclonus or 
robust motor abnormalities (Yokoi et al., 2012a). To gain additional insights into ε-SG 
function and the pathogenesis of MDS due to mutations in SGCE, we developed and 
characterized a novel Sgce gene-trap mouse model that disrupts expression of brain isoforms 
derived from exon 11b and other exons 3′ to exon 9.
2. Materials and methods
2.1. Developmental expression of Sgce
All mouse experiments were performed in accordance with the National Institutes of 
Health’s Guidelines for the Care and Use of Laboratory Animals and approved by our 
Institutional Animal Care and Use Committee. Expression patterns of Sgce transcripts were 
established in WT mice with relative quantitative reverse transcriptase-PCR (QRT-PCR) 
using tissues from cerebral cortex, cerebellum, hippocampus, ventral midbrain, striatum, 
thalamus, spinal cord, and liver. We examined 6 mice (3 male, 3 female) at 9 developmental 
time points (E15, P1, P7, P14, P21, P30, 2 mo, 6 mo, and 1 yr). Dissection of all brain 
regions which were readily identifiable in older mice was not possible at E15 and P1. SYBR 
Green-based QRT-PCR was performed with Ambion’s RETROscript® Reverse 
Transcription Kit and a LightCycler® 480 System (Roche, Indianapolis, IN, USA). One 
primer pair (Table S2, 85F and 85R) was designed to examine expression of all isoforms 
(Fig. 1). Expression of other isoforms was established by placing primers in exons 9 and 10 
(98F and 98R) or exons 9 and 11b (E9F and E11bR) with β-actin as the endogenous control 
(Fig. 1 and Table S2). Data was normalized to E15 cerebral cortex. Detailed methods are 
provided in a previous publication from our laboratory (Xiao et al., 2012).
2.2. Generation of Sgce gene-trap mice
One line of ES cells on a 129X1/SvJ × 129S1/Sv background and generated using the Gep-
SD5 vector (clone number CW509161 [CMHD-GT_148G1-3], Fig. 1) was obtained from 
The Center for Modeling Human Disease (CMHD, Ontario, Canada; www.cmhd.ca/
genetrap/vectors.html). The Gep-SD5 vector does not contain an internal ribosome entry 
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sequence. Due to the rules of nonsense-mediated decay, the selection transcript is only 
produced if the insertion site is close to the polyA near the 3′ end of the gene. The polyA 
sequence of the reporter gene (lacZ) is deleted which results in an unstable trapped transcript 
leading to hypomorphic mutants. DNA was extracted from cultured ES cells and used to 
confirm correct targeting of Sgce. Gene-trapped ES cells were injected into the blastocoel 
cavity of E3.5 C57BL/6 embryos using standard procedures. Male chimeras were bred to 
C57BL/6J female mice to establish coat color and germline transmission. The insertion site 
of the gene trap was identified with long-range PCR and confirmed with Sanger sequencing. 
We established that the terminal exons (3′ to exon 9) of Sgce were disrupted in 
homozygotes (SgceGt(148G1)Cmhd/Gt(148G1)Cmhd or SgceGt/Gt) and paternal heterozygotes 
(Sgcem+/pGt, m-maternal, p-paternal). Male Sgcem+/pGt mice were crossed to C57BL/6J 
female mice for 10 generations. Three primers (Table S2) were used for PCR-based 
genotyping with one primer located within the gene trap vector (Sgce_KO_V2L) and the 
two other primers flanking the gene-trap insertion within intron 9 of Sgce (NM_011360). 
The Mouse Direct PCR kit from Biotool (Houston, TX, USA) was used for genotyping with 
the following cycling conditions: 95°C for 5 min; 35 cycles at 95°C for 10 s, 60°C for 30 s, 
and 72°C for 30 s; and final at 72°C for 7 min. The WT allele yields a 552 bp amplicon 
whereas the gene-trap mutant allele generates a 393 bp amplicon. Sgcem+/pGt mice on the 
C57BL/6J background were crossed to BALB/c and 129S2 mice for 5 or more generations 
to determine if the occurrence of myoclonus depended on genetic background.
2.3. Sgce expression in gene-trap mice
Relative levels of mouse Sgce mRNA were determined in the cerebral cortex and cerebellum 
of 1-month-old WT, Sgcem+/pGt, SgcemGt/p+, and SgcemGt/pGt mice (n= 3/genotype) using 3 
primer pairs targeting different regions of Sgce (Fig. 1, Table S2). Sanger sequencing with 
two reverse primers in lacZ and one forward primer in exon 9 (Sgce_E9F) was used to 
establish in frame splicing of exon 9 to the Gep-SD5 vector sequence, and expression of 
Sgce/lacZ fusion transcript(s) was quantified with a forward primer in exon 9 (Sgce_E9F) 
and reverse primer in lacZ (β-Gal_R2, Table S2, Fig. 1). The predicted molecular weight of 
a chimeric ε-SG/β-gal fusion protein derived from the major ε-SG isoform and the Gep-SD5 
β-galactosidase was calculated at ~159 kDa using two independent algorithms (Stothard, 
2000, Bjellqvist et al., 1993). Of note, the chimeric protein harbors 25 amino acids between 
the end of ε-SG and the first methionine of β-galactosidase (Fig. S1). Mouse β-actin was 
used as the endogenous control. To ascertain spatial expression patterns, relative levels of 
mouse Sgce mRNA were determined in 6 brain regions (cerebral cortex, cerebellum, 
hippocampus, striatum, thalamus, and midbrain), cervical spinal cord, and liver harvested 
from 8 adult mice (3-month old, 4 males and 4 females) of WT, Sgcem+/pGt, and SgcemGt/pGt 
genotypes. SYBR Green-based QRT-PCR was performed using 3 primer pairs targeting 
different regions of Sgce (Fig. 1, Table S2). Mouse β-actin was used as the endogenous 
control. SgcemGt/p+ mice were not included in region of interest analyses since they showed 
no significant expression differences from WT mice in cerebral cortex and cerebellum 
(Table S3).
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2.4. Immunoaffinity purification (IAP) and mass spectrometry analyses
Antibodies used for IAP and Western blotting included pan-ε-SG antibody esg3788, pan-ε-
SG antibody esg3790, and brain-specific antibody esg2-1358 (Waite et al., 2016). The 
esg2-1358 antibody was generated against a short peptide (NH2-C-
QRFEVNGIPEERKLTEAMSL-COOH) derived exclusively from exon 11b (Waite et al., 
2016). The pan-ε-SG antibodies esg3788 and esg3790 were raised in rabbits immunized 
with a thioredoxin fusion protein containing the entire C-terminal intracellular domain of 
mouse ε-SG (NP_035490.3) that was used to generate previous ε-SG antibodies (Esapa et 
al., 2007). The anti-β-dystroglycan monoclonal antibody MANDAG2, developed by G.E. 
Morris, was obtained through the Developmental Studies Hybridoma Bank. Whole brain 
tissues from C57BL/6J WT and Sgcem+/pGt (all 3-month-old male) were snap frozen in 
liquid nitrogen and homogenized in digitonin (Merck Chemicals, Darmstadt, Germany) lysis 
buffer [1% digitonin (w/v), 150mM NaCl, 50mM Tris pH 8.0, 1mM EGTA, 1mM sodium 
orthovanadate and cOmplete™ Protease Inhibitor Cocktail (Roche, West Sussex, UK)], 
clarified and pre-cleared on protein A-agarose beads as previously described (Esapa et al., 
2007). Lysates were then incubated with antibody-conjugated protein A-agarose beads 
overnight at 4°C. Proteins were eluted from the beads via incubation in 2° non-reducing 
Laemmli buffer at 60°C for 30 minutes followed by boiling at 95°C for 5 minutes. DTT was 
added to the elution at a final concentration of 50 mM, and the elution was boiled at 95°C 
for 5 min. An aliquot of each IAP elution was analyzed via Western blot for enrichment of 
ε-SG and β-dystroglycan. The remaining eluate was resolved on a 4–12% gradient NuPAGE 
Novex Bis-Tris gel (Invitrogen, Loughborough, UK) for 10 min, and fixed in 50% (v/v) 
methanol with 4% (v/v) acetic acid for 15 min. The gel was stained using colloidal 
Coomassie InstantBlue protein stain (Expedeon, Swavesey, UK) for 1 hr, then destained in 
ultrapure water before each elution was excised in its entirety as two gel plugs. Gel plugs 
were sent for in-gel tryptic digest followed by Velos Orbitrap mass spectrometry at the 
Advanced Mass Spectrometry Facility (University of Birmingham-England). Data analysis 
was carried out using Proteome Discoverer (Thermo Scientific, Loughborough, UK) with 
the SEQUEST search algorithm.
2.5. X-gal staining
X-gal staining was performed with a LacZ Detection Kit for Tissues (InvivoGen San Diego, 
CA) following the manufacturer’s protocol. Briefly, adult (3-month old) Sgcem+/pGt mice 
were transcardially perfused with normal saline followed by 4% paraformaldehyde in 0.1M 
phosphate buffered saline (PBS) with 2 mM MgCl2 (pH 7.4). Brains were then placed into a 
cryoprotection solution (30% sucrose in 0.1M phosphate buffer [PB] with 2 mM MgCl2) 
overnight. Coronal and sagittal cryosections (40 μm) were acquired and rinsed in PBS (2mM 
MgCl2, pH 7.4). Floating sections were then incubated with the staining solution (6 mM 
potassium ferricyanide, 6 mM potassium ferrocyanide, 2 mM MgCl2, 0.02% Igepal, 0.01% 
sodium deoxycholate, and 1 mg/ml X-gal solution in PBS) for 48 hrs at 37°C. Sections then 
rinsed with PBS, mounted, dehydrated and coverslipped.
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2.6. Biogenic monoamines
Striatum was acutely harvested from 3 male and 3 female WT and Sgcem+/pGt mice at 3-
months of age. All subsequent processing was completed by the Vanderbilt University 
Neurochemistry Core. Tissue samples were homogenized with a dismembrator in a solution 
(pH 3.8) containing 0.1M trichloroacetic acid (TCA), 0.01 M sodium acetate, 0.0001 M 
EDTA, 5 ng/ml isoproterenol (as internal standard) and 10.5 % methanol. Ten microliters of 
homogenates were collected for assay of protein concentrations. Samples were then spun in 
a microcentrifuge at 10,000 g for 20 min and the supernatant was removed for monoamine 
analysis. Biogenic amines were determined by high-pressure liquid chromatography 
utilizing an Antec Decade II (oxidation: 0.65) electrochemical detector operated at 33°C. 
Supernatants (20 μl) were injected using a Water 2707 autosampler onto a Phenomenex 
Kintex (2.6 u, 100 A) C18 HPLC column (100 × 4.60 mm). Biogenic amines were eluted 
with a mobile phase consisting of 89.5% 0.1M TCA, 0.01 M sodium acetate, 0.0001 M 
EDTA and 10.5 % methanol (pH 3.8). Solvents were delivered at 0.6 ml/min using a Waters 
515 HPLC pump. Using this HPLC solvent the following biogenic amines were eluted in the 
following order: noradrenaline, 3, 4-dihydroxyphenylacetic acid (DOPAC); dopamine (DA); 
5-hydroxyindoleacetic acid (5-HIAA); homovanillic acid (HVA); 5-hydroxytryptophan (5-
HT); and 3-methoxytyramine (3-MT). HPLC control and data acquisition were managed by 
Empower software.
Protein concentrations were determined with a BCA Protein Assay Kit (ThermoFisher 
Scientific, Waltham, MA, USA). Ten microliter volumes of tissue homogenate were 
distributed onto a 96-well plate and 200 μl of mixed BCA reagent (25 ml of Protein Reagent 
A is mixed with 500 μl of Protein Reagent B) was added. The plate was then incubated for 2 
hrs at room temperature for color development. A BSA standard curve was simultaneously 
run. Absorbance was measured with a POLARstar Omega plate reader (BMG LABTECH, 
Cary, NC, USA).
2.7. Behavioral assessments
Adult (3-month-old) Sgcem+/pGt mice and gender-matched WT littermates were subjected to 
a battery of motor and behavioral examinations including open-field activity, rotarod, 
vertical rope climbing, raised-beam task, grip strength, gait analysis (DigiGait™), 
dominance tube, and cross-maze test as described in a recent publication from our laboratory 
(Xiao et al., 2016). Mice were weighted weekly. Video recordings and righting reflex assays 
were performed prior to weaning in independent groups of WT and Sgcem+/pGt mice.
WT and Sgce mutant mice were observed for the presence of spontaneous and stimulus-
induced (audiogenic [100 dB, 40 ms, 1 Hz]; tail, trunk and limb displacement with a 
microspatula; snout tap; and tail pinch) abnormal movements (tonus, clonus, tremor, 
twisting, bobbing, wagging, sustained flexion, and sustained extension; Table S4) on a daily 
basis from Postnatal Day 1 (P1) through P30 and then 3X weekly through 6 months of age. 
Although assessments were qualitative, abnormal movements were most apparent between 
P10 and P20, particularly P12 to P16.
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An initial cohort of 10 Postnatal Day 14 (P14) mice (all males, 5 WT and 5 Sgcem+/pGt) was 
videotaped for 5 min. Each mouse was placed in a clear rectangular arena (18 cm x 30 cm) 
and subjected to limb, tail and truncal displacements with a microspatula. The videotapes 
were scored by 3 raters blinded to genotype using an adaption of a previously published 
rating scale (Raike et al., 2012). This ordinal scale was utilized to score all abnormal 
movements in five body regions (face, neck, trunk, forelimbs, and hindlimbs): 0 - absent 
abnormal movement, 1- slight and intermittent, 2 - mild and common or moderate and 
intermittent, 3 - moderate and common, or 4 - marked and prolonged (Table S4). In addition, 
specific types of involuntary movements (tonus, clonus, tremor, twisting, bobbing, wagging, 
sustained extension, and sustained flexion) were rated in binary fashion as absent (0) or 
present (1).
A second cohort of 20 P16 mice (WT [n = 10] and Sgcem+/pGt [n = 10]), (5 males and 5 
females for each genotype) was videotaped for a total of 6 min of open-field behavior 
acquired in 1-min bins and scored by 3 blinded raters. Mice were placed alone in a clear 
plastic cage (18 cm × 30 cm) for videotaping and returned to their home cages between 
video sessions.
2.8. Whole-genome gene-expression analysis
Total RNA from mouse cerebellum was isolated from 6 adult (10 month-old) Sgcem+/pGt 
mice (3 males and 3 females) and 6 age- and gender-matched WT controls (Ambion™ TRI 
Reagent®, ThermoFisher Scientific). The quality of total RNA was assessed with a 
NanoDrop® ND-1000 spectrophotometer (NanoDrop Technologies) and RNA integrity was 
verified with an Agilent 2100 Bioanalyzer using the Agilent RNA 6000 Nano kit. Whole-
genome gene-expression data was generated with the Affymetrix GeneChip® Mouse Gene 
2.0 ST Array (Santa Clara, CA, USA). This array was designed using data from RefSeq 
(release 51), Ensembl (release 65) and lncRNA db and provides comprehensive coverage of 
over 30,000 mRNA transcripts and 2000 lincRNA transcripts. The 2.0 ST Array was 
designed with a median of 22 25-mer probes per transcript. Each array includes background 
antigenomic probes, poly-A controls and hybridization controls. Target RNA was first 
reverse transcribed into cDNA, followed by in-vitro transcription to generate biotin-labelled 
cRNA for subsequent hybridization. Hybridized target cRNA were stained with streptavidin 
phycoerythrin and scanned using an Affymetrix GeneArray Scanner.
Data were processed using Affymetrix Expression Console software that incorporates the 
Robust Multi-array Average (RMA) normalization algorithm. Genes were annotated using 
Affymetrix MoGene 2.0 ST, V.1, release 35 annotation files from NetAffx™ server of 
Affymetrix. The RMA-normalized .chp files were summarized further with GeneSpring 
GX® 13.1.1 (Agilent® Technologies, Santa Clara, CA). Scatter plots were used to access the 
reproducibility of gene expression within genotypes. A t-test statistic was used in identifying 
significantly dysregulated genes (p ≤ 0.05) between WT and Sgcem+/pGt mice. Differential 
gene expression was also analyzed using a False Discovery Rate (FDR) corrected p ≤ 0.05 
(Benjamini and Heller, 2008). A heat map created using unsupervised hierarchical clustering 
with average linkage and Euclidean distance and a volcano plot were used to visualize 
differential gene expression. Using WebGestalt (WEB-based GEne SeT AnaLysis Toolkit) 
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and Ingenuity Pathway Analysis (IPA), we investigated the effects of differentially regulated 
genes on pathways (KEGG, Kyoto Encyclopedia of Genes and Genomes) and molecular/
cellular networks (Zhang et al., 2005).
To validate data obtained with the Affymetrix GeneChip® Mouse Gene 2.0 ST Array, we 
selected 6 up-regulated and 6 down-regulated genes moderately expressed in cerebellum, 
and 3 genes related to the DGC, for QRT-PCR. Using TaqMan® probes, QRT-PCR was 
performed on the Roche LightCycler® 480 system with primers designed using the Roche 
Universal ProbeLibrary Assay Design Center. A total of 16 cerebellar RNA samples from 
WT and Sgcem+/pGt mice (8 males and 8 females in each group, including the 6 samples 
used for whole-genome gene-expression analysis) were employed for validation with β-actin 
as the endogenous control. Technical triplicates were performed for all samples and median 
values were utilized for statistical analysis.
2.9. Statistics
ANOVA with post-hoc tests was used to determine the effects of genotype and gender on 
parametric behavioral measures. The Mann-Whitney test was used to determine the effects 
of genotype within gender for a non-parametric behavioral measure (slips on the raised 
beam task). Two-tailed t-tests were used to establish the effects of genotype on monoamine 
levels in striatum. Fisher’s exact test was used to determine the effects of genotype on the 
results of dominance tube testing. An alpha (α) of 0.05 was chosen for statistical 
significance.
3. Results
3.1 Expression of Sgce is developmentally regulated
Overall, brain expression of total (Fig. 1C) and brain-specific (Fig. 1E) Sgce increased with 
increasing postnatal age (p < 0.0001, for both). There was a significant effect of region on 
expression of all Sgce isoforms (primers 85F and 85R), “long” isoforms (primers 98F and 
98R), and the brain-specific isoform derived, in part, from exon 11b (p < 0.0001, for all). 
The highest expression levels for all isoforms and the brain-specific isoform were detected 
in 2-month-old mouse brain (Fig. 1). In general, cerebellar levels of all isoforms and the 
brain-specific isoform were 2 to 3 fold higher than hippocampus and cerebral cortex. In 
older adult mice (1 yr), expression of all isoforms and the brain-specific isoform were 
similar in cerebellum and striatum. The brain-specific isoform was not detected in liver and 
total Sgce mRNA was very low in this non-neural tissue.
3.2 Sgce is maternally imprinted
Male and female heterozygous and homozygous mice were fertile and pups of all genotypes 
and both genders were born at normal Mendelian ratios. As seen in Table 2, there were 
significant effects of gender (F1,59 = 135.2, p < 0.0001) and genotype (F1,59 = 78.1, p < 
0.0001) on weights in 3-month-old mice (Table 2). Overall, Sgcem+/pGt mice were 10 to 
15% smaller than their WT littermates.
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Overall, long isoforms comprised roughly 70% of all isoforms in Sgce+/+ mice. More 
exclusively, the brain-specific isoform derived from exon 11b only comprised 10% of total 
Sgce (Table 3). Total expression of Sgce transcripts was reduced by approximately 60 to 
70% in Sgcem+/pGt and SgcemGt/pGt mice and unchanged in SgcemGt/p+ mice (Tables 3 and 
S3). Sanger sequencing using a forward primer in exon 9 (Sgce_E9F) and two reverse 
primers in lacZ (β_Gal_R1 and β_Gal_R2) yielded Sgce/lacZ fusion amplicons (716 and 
329 bp, respectively). QRT-PCR showed that long isoforms including the brain-specific 
isoform were not expressed in Sgcem+/pGt and SgcemGt/pGt mice (Table 3). However, 
expression of short Sgce isoforms and Sgce/lacZ fusion transcript(s) was preserved. 
Expression levels of fusion transcript(s) detected with random decamers were about twice 
the levels obtained with oligo(dT) primers (Table 3 and S3).
3.3 Sgcem+/pGt mice express reduced levels of ε-SG
ε-SG has been previously shown to form part of dystrophin-associated protein complexes in 
the brain that contain β-, δ- and ζ-sarcoglycans and β-dystroglycan (Waite et al., 2016). 
Therefore, we performed IAP and mass spectrometry analyses to investigate whether these 
complexes were disrupted in the Sgcem+/pGt mice compared to WT littermates. IAPs were 
performed with two different antibodies to enrich for total ε-SG (esg3788) or the brain-
specific ε-SG isoform specifically (esg2-1358). Purification of all ε-SG isoforms was 
verified by Western blot analysis using an ε-SG polyclonal antibody (Figs. 2 and S2). Both 
the ubiquitous and brain-specific ε-SG isoforms were enriched in the esg3788 IAP and the 
brain-specific ε-SG isoforms in the esg2-1358 IAP from WT brain tissue. However, there 
was a major reduction in detectable ε-SG in both IAPs from the Sgcem+/pGt tissue leaving a 
residual immunoglobulin-related signal of approximately 50 kDa. Western blot of the IAPs 
using an anti-β-dystroglycan antibody demonstrated co-purification of the DGC component 
β-dystroglycan in the esg3788 IAP from WT tissue and to a lesser extent in the esg2-1358 
IAP. By contrast, there was only trace detection of β-dystroglycan in the esg3788 IAP from 
Sgcem+/pGt tissue that was absent in the esg2-1358 IAP. With high exposure, a putative ε-
SG/β-gal band was seen at ~159 kDa in the esg3788 IAP from Sgcem+/pGt tissue (Fig. S2).
The remaining immunoaffinity-purified material from all samples was separated by 
polyacrylamide gel electrophoresis and stained with colloidal Coomassie blue. Each sample 
was excised as two gel bands and analysed via mass spectrometry to identify the protein 
constituents. Multiple high confidence ε-, β-, δ- and ζ-sarcoglycan peptides were detected in 
the esg3788 and esg2-1358 IAPs from WT tissue indicating purification of the entire brain 
sarcoglycan complex. Only a subset of these peptides was detected in the esg3788 IAP from 
the Sgcem+/pGt mice (Table 4). Additionally, the spectral counts for each sarcoglycan were 
reduced in Sgcem+/pGt mice versus WT littermates, reflecting a lower abundance of the 
sarcoglycans in the esg3788 IAP from Sgcem+/pGt mice (Table S5). However, there was a 
complete absence of detectable sarcoglycan peptides in the esg2-1358 IAP from Sgcem+/pGt 
tissue indicating a loss of brain-specific ε-SG isoform containing protein complexes.
Both the Western blot and mass spectrometry data from the IAPs indicate a significant 
reduction in ε-sarcoglycan protein isoforms in Sgcem+/pGt mice compared with WT 
littermates with a complete loss of detectable ε-SG isoform 2. However, detection of β-
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dystroglycan by Western blot and ε-, β-, δ- and ζ-sarcoglycans using mass spectrometry in 
the esg3788 IAP indicate the existence of residual ε-SG containing sarcoglycan complexes 
and dystrophin-associated protein complexes in the Sgcem+/pGt mice.
3.4 Sgce is widely expressed in the central nervous system (CNS)
In Sgcem+/pGt mouse brain, X-gal staining was seen throughout the CNS (Fig. 3). In 
cerebellum, staining was prominent in the molecular layer with weaker expression in the 
granule cell layer and cerebellar nuclei (Fig. 3B). In the basal ganglia, staining in the 
caudate-putamen and lateral globus pallidus was more intense than that seen in the 
subthalamic nucleus and substantia nigra (Fig. 3C). In cerebral cortex, staining was most 
prominent within Layer V but also stood out in Layers II and III (Figs. 3A & D). In 
hippocampus, modest staining intensity was seen in the pyramidal cell layer and dentate 
gyrus (Fig. 3G).
3.5 Sgcem+/pGt mice have normal monoamine levels in the striatum
There were no significant effects of gender or genotype on striatal monoamine levels (Table 
S6). However, noradrenaline levels trended higher in Sgcem+/pGt mice.
3.6. Abnormal gait and appendicular posturing are seen in preweanling Sgcem+/pGt mice
No evidence of myoclonus or limb dystonia was noted while Sgcem+/pGt mice on the 
C57BL/6J background or mixed C57BL/6JxBABL/c and C57BL/6Jx129S2 backgrounds 
were routinely observed in their home cages or during open field behavior from the early 
postnatal period through 1.5 yrs of age. Moreover, myoclonus was not observed in response 
to audiogenic or tactile stimuli. However, abnormal hindlimb posturing in response to 
perturbations and “tiptoe” walking were significantly more common in preweanling 
Sgcem+/pGt mice (Videos S1 & S2) in comparison with WT littermates. Male and female 
Sgcem+/pGt mice had significantly higher scores than WT littermates (Table 5) on the rating 
scale for abnormal movements (Table S4). With the use of perturbations, the identification of 
abnormal motor phenotypes showed a low false positive rate. False positive and negative 
rates were higher with ratings of unperturbed open-field behavior (Table 5).
3.7. Sgcem+/pGt mice show evidence of mild abnormalities on measures of gait, open-field 
activity and behavior
In the preweanling period, Sgcem+/pGt mice and WT littermates showed no righting time 
differences (Fig. S3). In adult mice, there were significant effects of gender (F1,60 = 84.1, p 
< 0.0001) and genotype (F1,60 = 91.0, p < 0.0001) on grip strength (Table 2). Male WT mice 
exhibited greater grip strength than Sgcem+/pGt littermates (mean difference = 55 g). The 
effect of genotype was similar in female mice (mean difference = 54 g). However, after 
normalized by weight, the effect of genotype on grip strength was no longer apparent (p = 
0.56). There were no effects of genotype on rope climbing or tube dominance. There was a 
notable effect of genotype (F1,60 = 15.2, p = 0.0003) but no effect of gender or the genotype-
gender interaction on cross-maze scores. Male and female Sgcem+/pGt mice had significantly 
lower scores than their gender-matched WT littermates on the cross-maze test (p < 0.05, for 
both).
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Sgcem+/pGt mice were less active than their WT littermates on multiple parameters open-
field activity (Table 2). There were significant genotype*gender interactions with female 
mice showing larger effects of genotype on open-field assays of distance traveled, jump 
count, and ambulatory count (p = 0.0001, 0.0036, and 0.014, respectively). There were large 
effects of genotype on stereotypic counts (F1,60 = 32.65, p < 0.0001) and ambulatory 
episodes (F1,60 = 10.89, p = 0.0016) but no significant effects of the genotype*gender 
interaction.
DigiGait™ analyses showed minor effects of genotype (Table 2) on several gait parameters. 
Male Sgcem+/pGt mice had shorter forepaw (p = 0.004) and hindpaw (p < 0.0001) stride 
lengths and higher forepaw and hindpaw stride frequencies (p <0.0001, for both) than WT 
gender-matched littermates. These differences did not reach statistical significance in female 
mice. Forepaw areas were smaller in Sgcem+/pGt mice than WT littermates (F1,60 = 17.1, p = 
0.0001). Overall, hindpaw areas were also smaller in Sgcem+/pGt mice than WT littermates 
(F1,60 = 30.6, p < 0.0001) but there was a genotype*gender interaction (F1,60 = 18.8, p < 
0.0001) with male mice showing a more marked effect of the mutant allele. There was a 
small overall effect of genotype on forepaw stance width (F1,60 = 4.1, p = 0.047). Hindpaw 
stance width was narrower in Sgcem+/pGt mice than WT littermates (F1,60 = 23.33, p < 
0.0001) although the difference between Sgcem+/pGt mice and WT females did not reach 
statistical significance (p = 0.060).
On the rotarod, both Sgcem+/pGt mice and WT littermates showed increased latencies to fall 
from Day 1 through Day 5 but there was no effect of genotype (Fig. 4A). On the raised-
beam task, there were no significant effects of gender or genotype on beam traversal times 
(Figs. 4B & C). On the 9-mm round beam, male and female Sgcem+/pGt mice had more slips 
than gender-matched WT littermates (p = 0.016 and p = 0.22, respectively). Male and female 
Sgcem+/pGt mice also had more slips on the 9-mm square beam than gender-matched WT 
littermates (p = 0.0003 and p = 0.035, respectively).
3.8. Whole-genome gene expression abnormalities distinguish Sgcem+/pGt mice from WT 
littermates
The high linear correlations among scatter plots in male and female WT and Sgcem+/pGt 
mice support the reproducibility of our whole-genome gene expression data (Figs. S4 & S5). 
Differential gene expression was visualized with a heat map (Fig. S6) and volcano plot (Fig. 
S7). The symmetric volcano plot also attests to the quality of our gene expression analyses. 
With FDR ≤ 0.05 and fold change (FC) ≥ 2.0, we ended up with only two genes (Sgce and 
1700016P03Rik) that were significantly dysregulated (Table 6, Fig. S7). Without correction 
for familywise error, we found 6 and 5 genes that were down- or up-regulated by 1.5X, 
respectively (Table 6). At a 1.25X FC, we found 38 and 31 genes that were significantly up- 
or down-regulated, respectively. QRT-PCR corroborated the direction and relative magnitude 
of differential expression for 11/12 genes that were assayed (Table 7).
Genes showing the largest up-regulation (Table 6) included the immediate-early gene Fos 
and three members of the nuclear receptor subfamily 4 (Nr4a3, Nr4a2 and Nr4a1). Other up-
regulated genes encode cell-cycle (Cdkn1a) or complement (Cd55) proteins or small 
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nucleolar RNAs (Snord35a, Snora35, and Snord14e). The top down-regulated genes (Table 
6) included those encoding an E3-ubiquitin ligase (Mid1) and islet cell autoantigen 1 (Ica1).
A large collection of genes directly or indirectly associated with the dystrophin-glycoprotein 
complex were specifically examined for evidence of differential expression between WT and 
Sgcem+/pGt cerebellum (Table S7). Based on BioGPS (biogps.org) and the Allen Brain Atlas 
(www.brain-map.org), the majority of these genes show significant expression in 
cerebellum. The largest, albeit modest, FCs were seen for Stx1A (syntaxin 1A) and Cav3 
(caveolin). There was no significant up-regulation of other sarcoglycans (α β, γ, δ, or ζ).
There were few enriched KEGG pathways for up-regulated genes and none for down-
regulated genes. The largest collection of significantly up-regulated genes was associated 
with systemic lupus erythematosus and the ribosome (Table S8). IPA analysis indicated that 
a relatively large percentage of up- or down-regulated genes are involved in cell cycle, 
cellular development, and cell death and survival (Table S9). Regulation of eIF4 and 
p70S6K signaling and mTOR signaling were the top canonical pathway for up-regulated 
genes. Significant upstream regulators of dysregulated genes are shown in Table S10 and 
include Ifnar1, Crem, and Creb1 for up-regulated genes, and Tnfrsf4 and Nfe2l1 for down-
regulated genes. Interactome analysis identified NF-κB and TP53 as the major hubs for up- 
and down-regulated genes, respectively (Fig. 5). Akt and NFE2L2 were secondary hubs for 
up- and down-regulated genes, respectively.
4. Discussion
4.1 Splice variants of SGCE and Sgce
Human SGCE, located on the reverse strand of Chr. 7q21.3 (CRCh38/hg38), has 4 
Consensus CDS isoforms (Fig. 1) and 4 RefSeq isoforms. Mouse Sgce, located on the 
reverse strand of Chr. 6qA1 (CRCm38/mm10) has 4 Consensus CDS isoforms and 5 RefSeq 
isoforms. The major isoform (NM_011360) harbors 11 exons with exon 8, but without exons 
1a, 11, and 11b; while the brain-specific isoform (NM_001130189) also harbors 11 exons 
with exon 11b, but without exons 1a and 8. The gene-trap insertion site within intron 9 of 
NM_011360 is predicted to disrupt all isoforms with the exception of AK132210 (9 exons 
and without exons 1a, 10, 11, and 12) and ENSMUST00000139029. Total Sgce expression 
was reduced by 60 to 70% in our mouse model which exhibited mild motor and cognitive 
abnormalities along with stimulus-induced appendicular posturing. Presumably, residual 
expression of Sgce was enough to prevent the appearance of overt myoclonus. Amino acids 
1 to 317 of mouse and human ε-SG are located in the extracellular space with only 23% of 
the full-length protein located in the cytoplasmic space (amino acids 339 – 437). The few 
SGCE mutations causally-associated with DYT11 and localized to the cytoplasmic domain 
of ε-SG are frameshifts and likely associated with nonsense-mediated decay (Valente et al., 
2005, Asmus et al., 2005). However, it is possible that the failure to include all alternative 
exons, including exon 11b, in screening efforts has contributed to the relatively low reported 
frequency of SGCE mutations in subjects with MDS (Ritz et al., 2009, Peall et al., 2014, 
Valente et al., 2005). Moreover, our data suggest that the long isoforms of Sgce are required 
for entirely normal motor and cognitive functioning, at least in mice.
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4.2 Long isoforms of Sgce are widely expressed in the CNS and enriched in cerebellum
Compatible with data reported by BioGPS (BioGPS.org) and Allen Brain Atlas (www.brain-
map.org), we showed that Sgce is widely expressed in mouse brain from the early postnatal 
period through adulthood and modestly enriched in cerebellum in comparison with other 
sensorimotor structures such as striatum, thalamus and spinal cord. The expression patterns 
of Sgce identified with X-gal staining in our mouse model are similar to those reported in 
rats with in situ hybridization (Xiao and LeDoux, 2003). For the data described herein, β-gal 
staining was derived from a chimeric ε-SG/β-gal fusion protein and appears to represent 
expression of the major isoform and/or other protein isoforms that are derived from exon 10 
and exons 3′ to exon 10. The β-gal staining does not incorporate expression of the shortest 
Sgce isoforms. IAP-mass spectrometry and QRT-PCR showed that the major and brain-
specific isoforms of Sgce were eliminated in Sgcem+/pGt mice. However, short isoforms 
terminating 5′ to intron 9 and small amounts of a chimeric ε-SG/β-gal fusion protein were 
preserved and may have compensated, at least in part, for absence of the major and brain-
specific isoforms.
4.3 Sgcem+/pGt mice exhibit mild behavioral and motor abnormalities
As reported previously in humans and Sgce null mice, our Sgce mutant mice generated with 
gene-trap technology showed clear-cut maternal imprinting such that Sgce expression from 
both SgcemGt/pGt and Sgcem+/pGt mice was absent (Yokoi et al., 2005). Male and female 
Sgcem+/pGt mice were smaller than WT littermates and showed several abnormalities on 
behavioral and motor testing. Male and female Sgcem+/pGt mice showed reduced scores on 
the cross-maze test. Based on the results of rope climbing, rotarod and open-field activity, it 
is unlikely that the significantly lower scores on the cross-maze test were due to motor 
deficits. Instead, the cross-maze scores are a likely manifestation of increased anxiety in 
Sgcem+/pGt mice although contributions from cognitive deficits cannot be excluded (Salimov 
et al., 1995, Salimov et al., 1996). Anxiety is a well-known psychiatric co-morbidity in 
human myoclonus-syndrome due to mutations in SGCE (Peall et al., 2013, Peall et al., 
2016). Accordingly, it is possible that deleterious sequence variants localized to terminal 
exons of SGCE could be risk factors for human anxiety even if not associated with dystonia 
and/or myoclonus.
Dystonia or dystonic-like posturing was not described in previously published murine 
models of DYT11 (Yokoi et al., 2005, Yokoi et al., 2006, Yokoi et al., 2012a, Yokoi et al., 
2012b). Stimulus-induced flexion posturing was seen in our preweanling Sgcem+/pGt mice 
mainly between P14 and P16, a key period for development of cerebellar Purkinje cells and 
cerebellar cortex (Kano and Hashimoto, 2012). In theory, Purkinje cells and/or local area 
networks could be unstable until additional maturation has been completed. In this regard, 
stimulus-induced dystonia, seen in humans with paroxysmal kinesigenic dyskinesias due to 
mutation in PRRT2, often becomes manifest during childhood (Erro et al., 2014), and 
transient dystonia of infancy usually manifests between 5 and 10 months of age and then 
gradually disappears after 3 months to 5 years (Bonnet et al., 2010). Given that dystonia 
remains an inexact clinical diagnosis, both in mice and men, we have restricted our 
description to flexion posturing. We could not illicit abnormal posturing in postweanling 
mice or extensor posturing in preweanling mice. Sgcem+/pGt mice also exhibited a “tiptoe” 
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gait with raised caudal trunk and narrowed hindlimb stance widths. The narrowed hindlimb 
stance widths persisted into adulthood (Table 2). Tiptoe walking is not specific to dystonia 
or Sgcem+/pGt mice and has also been described in Yoshimura mice, a model of chronic 
cervical myelopathy (Wang et al., 2014). However, early gait abnormalities may be common 
in humans with SGCE mutations (Asmus et al., 2005). In one study, for example, all SGCE 
mutations carriers had a gait disorder, unsteadiness or frequent falls before 18 months of age 
(Asmus et al., 2005).
Our gene-trap Sgce mouse model showed some similarities and a few important differences 
from previously reported Sgce null and conditional KO mice, as well as Tor1a-Sgce double 
null mice. All Sgce models have shown impaired performance on the raised-beam task with 
increased numbers of slips (Yokoi et al., 2006, Yokoi et al., 2012a, Yokoi et al., 2012b, 
Yokoi et al., 2010). Sgce null mice had increased vertical open-field motor activity, anxiety-
like behavior, myoclonus and increased striatal dopamine (Yokoi et al., 2006). In 
comparison, our gene-trap model also showed evidence of anxiety but exhibited reduced 
vertical open-field motor activity, had no evidence of myoclonus and striatal dopamine 
levels were normal. In addition, slips on the raised-beam task are not specific to Sgce models 
and have been reported in Tor1a, Thap1, and Ciz1 models of dystonia (Yokoi et al., 2015, 
Ruiz et al., 2015, Xiao et al., 2016, Zhao et al., 2008). Increased slips on the raised beam 
task have been reported in heterozygous Tor1a null mice and hMT1 transgenic mice that 
overexpress mutant human torsinA (Zhao et al., 2008, Dang et al., 2005, Song et al., 2014).
4.4 Gene expression abnormalities in Sgcem+/pGt mice
IAP-mass spectrometry showed that brain-specific ε-SG interacts with β-SG, δ-SG, and ζ-
SG. Gene-expression data did not show evidence for their compensatory up-regulation in 
Sgcem+/pGt mice. Furthermore, there was no apparent up-regulation for other components of 
the DGC at the transcript level. Given the modest phenotypes in our Sgcem+/pGt mice, it 
seems that short isoforms of ε-SG were able to partially compensate for loss of the major 
and brain-specific isoforms and other long isoforms.
Based on IPA analysis, it appears that up- and/or down-regulation of genes in various cell 
cycle, cellular development, and cell death and survival pathways served to compensate for 
ε-SG deficiency in our mouse model. However, we cannot exclude the possibility that some 
of these changes in gene expression were not due to novel effects of mutant ε-SG/β-gal 
fusion protein(s) that resulted from insertion of the Gep-SD5 gene-trap vector into intron 9 
of Sgce. Although a single-pass transmembrane cell-surface protein seemingly involved in 
synaptic transmission, our gene expression data suggests that ε-SG shows functional overlap 
with other dystonia proteins such as TAF1, CIZ1, torsinA, THAP1, and Gα(olf) which play 
direct or indirect roles in cell cycle control, DNA repair and neurodevelopment (LeDoux et 
al., 2013, Xiao et al., 2016).
Several relatively distinct groups of genes showed up-regulation (Nr4a3, Fos, Nr4a2, Nr4a1, 
Cdkn1a, Cd55, Snord35a, Snora35 and Snord14e) or down-regulation (Mid1 and Ica1). 
Intermittent subclinical involuntary movements and/or anxiety could be responsible for 
differential up-regulation of the immediate-early genes Fos, Nr4a3, Nr4a2, and Nr4a1 in 
Sgcem+/pGt mice (Huguet et al., 2016). CDKN1A is an essential cell-cycle protein that 
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interacts with the dystonia-associated protein CIZ1 (LeDoux et al., 2013, Xiao et al., 2012) 
and CD55 regulates the complement system, an important player in neuronal differentiation 
(Stephan et al., 2012). Snord35a, Snora35 and Snord14e encode small nucleolar RNAs, a 
class of RNA molecules that contribute to modifications of rRNA and tRNAs such as 
methylation and pseudouridylation. MID1 functions as a ubiquitin ligase and regulator of 
mTOR signaling and plays an important role in neurodevelopment and neurodegeneration. 
Lack of MID1 causes abnormal development of the cerebellum (Lancioni et al., 2010).
Top up-regulated canonical pathways (eIF4, p7056K, mTOR) and IPA nodes (NF-kB, Akt) 
are related to intracellular pathways regulating the cell cycle. The Akt/mTOR component of 
this intracellular network has been shown to regulate neurite outgrowth in cerebellar granule 
cells (Okada et al., 2011) and the morphology of Purkinje cells (Thomanetz et al., 2013). 
The major hubs for down-regulated genes, TP53 and NFE2L2, can also be readily linked to 
cell cycle control and neurodevelopment. In cerebellum, elevation of NFE2L2 (alias NRF2) 
levels in beneficial in a mouse model of Alexander disease caused by autosomal mutation in 
GFAP (LaPash Daniels et al., 2012). TP53 regulates CDKN1A at the G1/S cell-cycle 
checkpoint. In aggregate, gene expression studies suggest that compensatory up- or down-
regulation of genes related to neurodevelopment and neuronal morphology may compensate 
for loss of major and brain-specific ε-SG isoforms.
5. Conclusions
Sgcem+/pGt mice show germline absence of major and brain-specific isoforms harboring 
exons 3′ to intron 9. Sgce was maternally-imprinted in our mouse model. Sgcem+/pGt mice 
exhibited tiptoe walking and occasional stimulus-induced appendicular flexion posturing in 
the preweanling period from P10 to P20. Adult Sgcem+/pGt mice showed increased slips on a 
raised-beam task, anxiety-like behavioral abnormalities, and narrowed hindlimb stance 
widths but no myoclonus or differences in striatal monoamines in comparison with WT 
littermates. Overall, adult Sgcem+/pGt mice were less active than WT littermates. There was 
no evidence for up-regulation of other sarcoglycans in Sgcem+/pGt mice. Genes differentially 
expressed between Sgcem+/pGt mice and WT littermates were involved in cell cycle, cellular 
development, and cell death and survival. Our gene-trap mice provide novel insights into the 
biology and pathobiology of ε-SG.
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Highlights
We generated a gene-trap mouse model with reduced expression of ε-sarcoglycan.
Sgce mutant mice exhibit a tiptoe gait and appendicular posturing.
Sgce mutant mice have altered gait dynamics and reduced open-field activity.
In the cerebellum, dysregulated genes were involved in cell cycle and 
development.
Short Sgce isoforms compensate for deficiency of major and brain-specific 
isoforms.
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Fig. 1. 
(A) Human SGCE Consensus CDS isoforms. (B) Mouse Sgce isoforms derived from 
Consensus CDS, Ensembl gene predictions and UCSC genes showing the location of the 
CMHD-GT_14G1-3 Gep-SD5 gene trap. Three distinct primer pairs (C, 85F/85R; D, 98F/
98R; and E, E9F/E11bR) were designed to examine Sgce expression in eight different 
tissues across nine developmental time points. (F) Protein structures of the major 
(NP_035490.3), longest (NP_001123660.1), brain-specific (NP_001123661), and shortest 
(BAE21034.1) mouse isoforms, and predicted chimeric ε-SG/β-gal fusion protein derived 
from the major isoform. Blue bars, transmembrane domain. Green bars, isoform specific 
domains. Red bar, protein sequence derived from exon 11b that includes a PDZ-binding 
motif. Pink bar, β-galactosidase.//, predicted sites of ε-SG/β-gal protein fusion. Also shown 
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are the approximate locations of primers that would amplify the corresponding regions of 
Sgce and hybrid transcripts. SA, splice acceptor. lacZ, gene encoding β-galactosidase. neo, 
neomycin resistance gene. SD, splice donor.
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Fig. 2. 
Western blots of immunoaffinity purifications (IAPs) of ε-SG-containing complexes from 
WT C57BL/6J and Sgcem+/pGt mice. The left three lanes contain proteins isolated from WT 
brain tissue whereas the right two lanes contain protein from Sgcem+/pGt brain tissue. Lanes 
are labelled with the antibody used to isolate proteins: PI, preimmune IgG; 3788, esg3788 
anti-ε-SG; 1358, esg2-1358 anti-ε-SG brain-specific isoform. The biotinylated anti-ε-SG 
antibody detects both the major isoform (lower band, ε-SG 1) and brain-specific isoform 
(upper bands, ε-SG 2) of ε-SG in IAPs using the esg3788 anti-ε-SG antibody, and only the 
brain-specific isoform in IAPs using the esg2-1358 anti-ε-SG brain-specific isoform 
antibody. Western blot using the anti-β-dystroglycan antibody MANDAG2 showing co-
purifications of β-dystroglycan in the esg3788 and esg-1358 IAPs from WT tissue. β-
dystroglycan is severely reduced in the esg3788 IAP from Sgcem+/pGt brain tissue and absent 
in the esg-1358 IAP.
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Fig. 3. 
X-gal expression in Sgcem+/pGt mice. A parasagittal section (A) of Sgcem+/pGt mouse brain, 
showing intense reaction in the gray matter of cerebellar cortex, striatum and cerebral cortex. 
(B) Cerebellum. (C) Striatum. (D) Cerebral cortex. (E) Ventral midbrain. (F) Hypothalamus. 
(G) Hippocampus. R, rostral; V, ventral; AC, anterior commissure; MedDL, medial 
cerebellar nucleus, dorsolateral protuberance; CPU, caudate putamen; LGP, lateral globus 
pallidus; STN, subthalamic nucleus; SN, substantia nigra. Scale bar = 400 μm.
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Fig. 4. 
Performance of Sgcem+/pGt mice (n = 15 males and 15 females) and WT littermates (n = 18 
males and 16 females) on the rotarod (A) and raised beam tasks (B and C). Beam traversal 
times (B) and slips (C) were recorded for 4 different beams. *significant effect of genotype 
within gender (p<0.05)
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Fig. 5. 
Ingenuity interactome analysis of up-regulated (A) and down-regulated (B) genes in 
Sgcem+/pGt mouse cerebellum.
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Table 1
SGCE variant screening in myoclonus-dystonia syndrome
Study Subjects screened (positive) Exon 11b screened Mutation locations
Han et al (2003) 7 families (3) No Exons 3 and 7
Schüle et als (2004) 10 families (2) No Exons 2 and 7
Valente EM et al. (2005) 58 index patients (6) No Exons 3, 4, 5 and 9
Tezenas du Montcel et al. (2006) 76 index patients (16) Yes Exons 2, 3, 4, 6, 7, and 9
Gerrits et al. (2006) 31 index patients (7) No Exons 2, 3, 5, 6, 7
Nardocci N et al. (2008) 11 families (9) No Exons 3, 4, 6, and 7
Ritz K et al. (2009) 86 index patients (13) No Exons 2, 3, 5, 6, and 7
Asmus F et al. (2009) 23 index patients (7) Yes Exons 3, 6, 7, and 10
Carecchio M et al. (2013) 46 new index patients (8) No Exons 3, 4, 6, and 9
Peall KJ et al. (2014) 89 index patients (19) Yes Exons 3, 5, 6, 7 and 9
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Table 2
Effects of genotype and gender on weight and behavioral measures in 3-month-old mice. Ambulatory count, 
the total number of X + Y photo beam breaks while in ambulatory movement status. Stereotypic count, any 
partial-body movements that occur within the ambulatory box such as grooming, head-weaving or scratching. 
Vertical count, number of periods of continuous Z photo beam breaks. Jump count, the number of times that 
the mouse leaves the photo beam array for a period of time. Ambulatory episodes, the number of times the 
mouse has started moving after the resting delay has expired. Values are means ± SEM except for dominance 
tube.
Male Female
Sgce+/+ (n=18) Sgcem+/pGt (n=15) Sgce+/+ (n=16) Sgcem+/pGt (n=15)
Weight (g) 31.2 ± 0.7 26.3 ± 0.5* 24.9 ± 0.4 20.2 ± 0.4*
Grip strength (g) 329.2 ± 6.9 274.3 ± 5.8* 276.4 ± 4.5 222.1 ± 4.8*
Grip strength/weight 10.6 ± 0.3 10.4 ± 0.2 11.2 ± 0.2 11.0 ± 0.3
Dominance tube 53.3% 46.7% 49.0% 47.1%
Cross maze score (%) 33.5 ± 2.3 25.4 ± 2.0* 33.1 ± 2.5 23.5 ± 2.3*
Rope climbing (s) 5.4 ± 0.5 4.5 ± 0.4 4.1 ± 0.6 4.3 ± 0.4
Rope climbing/weight 0.17 ± 0.01 0.17 ± 0.01 0.16 ± 0.02 0.21 ± 0.02
Open field activity
 Distance traveled (cm) 1858.4 ± 52.0 1594.7 ± 30.4* 2455.7 ± 53.2 1798.7 ± 43.3*
 Ambulatory count 897.4 ± 32.7 782.1 ± 18.5* 1168.4 ± 31.4 904.2 ± 31.3*
 Stereotypic Count 2596.8 ± 102.3 2245.1 ± 42.1* 2607.0 ± 49.5 2183.5 ± 56.8*
 Vertical count 189.9 ± 11.2 187.5 ± 15.0 135.3 ± 10.7 101.4 ± 10.2*
 Jump count 35.1 ± 2.9 38.3 ± 2.7 45.9 ± 4.1 29.5 ± 2.4*
 Average velocity (cm/s) 36.2 ± 1.5 34.4 ± 1.6 43.5 ± 1.9 45.2 ± 2.1
 Ambulatory episodes 85.4 ± 6.0 75.9 ± 6.4 112.9 ± 6.2 85.2 ± 3.7*
DigiGait™
 Propel (s) Forelimb 0.127 ± 0.003 0.116 ± 0.003* 0.116 ± 0.004 0.110 ± 0.004
 Propel (s) Hindlimb 0.195 ± 0.003 0.168 ± 0.002* 0.175 ± 0.004 0.165 ± 0.002*
 Stride length (cm) Forelimb 7.06 ± 0.13 6.38 ± 0.10* 6.56 ± 0.15 6.44 ± 0.11
 Stride length (cm) Hindlimb 7.22 ± 0.09 6.45 ± 0.08* 6.75 ± 0.10 6.57 ± 0.06
 Stride Frequency (steps/s) Forelimb 2.87 ± 0.04 3.29 ± 0.03* 2.92 ± 0.06 3.04 ± 0.05
 Stride Frequency (steps/s) Hindlimb 2.81 ± 0.04 3.09 ± 0.04* 2.86 ± 0.05 3.00 ± 0.02*
 Stance width (cm) Forelimb 1.58 ± 0.02 1.49 ± 0.03* 1.44 ± 0.03 1.40 ± 0.03
 Stance width (cm) Hindlimb 2.60 ± 0.05 2.35 ± 0.04* 2.30 ± 0.02 2.21 ± 0.02*
 Step angle (deg) Forelimb 64.87 ± 1.83 65.81 ± 1.74 67.79 ± 1.49 65.63 ± 1.66
 Step angle (deg) Hindlimb 54.77 ± 1.62 55.93 ± 0.99 61.04 ± 1.32 59.54 ± 1.33
 Paw Area (cm2) Forelimb 0.23 ± 0.01 0.20 ± 0.01* 0.22 ± 0.01 0.19 ± 0.01*
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Male Female
Sgce+/+ (n=18) Sgcem+/pGt (n=15) Sgce+/+ (n=16) Sgcem+/pGt (n=15)
 Paw Area (cm2) Hindlimb 0.46 ± 0.01 0.38 ± 0.01* 0.41 ± 0.01 0.40 ± 0.01
*p < 0.05, for effect of genotype within gender.
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Table 4
Unique sarcoglycan peptides identified in wild-type and Sgcem+/pGt whole brain ε-SG immunoaffinity 
purifications (IAPs). For each IAP (wild-type versus Sgcem+/pGt tissue, esg3788 antibody versus esg2-1358 
antibody), all unique tryptic sarcoglycan peptides detected via mass spectrometry are included in the table. 
The ε-SG2 brain-specific peptides detected in wild-type tissue are in bold. Abbreviations: IAP, immunoaffinity 
purification; esg3788, anti-ε-SG antibody 3788; esg2-1358, anti-ε-SG2 antibody 1358.
Protein
esg3788 IAP esg2-1358 IAP
Wild-type Sgcem+/pGt Wild-type Sgcem+/pGt
ε-SG
TPYSDGVLYGSPTAENVGKPTIIEITAYNRR
None
QVSTYQEVVR QVSTYQEVVR QVSTYQEVVR
EVENPQNQLR EVENPQNQLR
FEVNGIPEER
KLTEAmSL
β-SG
RNENLVITGNNQPIVFQQGTTK RNENLVITGNNQPIVFQQGTTK RNENLVITGNNQPIVFQQGTTK
None
LPSSSSGDQSGSGDWVR LPSSSSGDQSGSGDWVR
THNILFSTDYETHEFHLPSGVK
TSITSDIGmQFFDPR TSITSDIGmQFFDPR TSITSDIGmQFFDPR
LcMcADGTLFK LcMcADGTLFK
GNEGVFIMGK GNEGVFIMGK
δ-SG
GVEINAEAGNMEAIcR GVEINAEAGNMEAIcR
None
LEGDSEFLQPLYAK LEGDSEFLQPLYAK LEGDSEFLQPLYAK
LLFSADDSEVVVGAER LLFSADDSEVVVGAER LLFSADDSEVVVGAER
VLGAEGTVFPK VLGAEGTVFPK VLGAEGTVFPK
VFEVcVcANGR VFEVcVcANGR
VLTQLVTGPK VLTQLVTGPK VLTQLVTGPK
SRPGNALYFK
SLVMEAPK
ζ-SG
ELHLQSTEGEIFLNADSIR ELHLQSTEGEIFLNADSIR
None
VLFSADEDEITIGAEK VLFSADEDEITIGAEK
LEGISEFLLPLYVK LEGISEFLLPLYVK LEGISEFLLPLYVK
LGNLPIGSFSSSTSSSNSR LGNLPIGSFSSSTSSSNSR
QTVYELcVcPnGK QTVYELcVcPnGK
GVQVSAAAGDFK GVQVSAAAGDFK GVQVSAAAGDFK
STDLDIQELK
VTGTEGAVFGHSVETPHIR
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Table 5
Blinded video analyses of abnormal movements in preweanling Sgcem+/pGt mice and WT littermates at P14 
and P16.
Sex, Genotypes (numbers, age) Total scorea (mean ± SEM) Number of genotype-phenotype matchesb Percent correct
M, WT (n=5, P14) 1.7 ± 1.2 4/5 80.0
M, Sgcem+/pGt (n=5, P14) 8.3 ± 3.3* 5/5 100.0
M, WT (n=10, P16) 18.7 ± 4.7 22/30 73.3
M, Sgcem+/pGt (n=10, P16) 36.0 ± 5.3* 18/30 60.0
F, WT (n=10, P16) 20.0 ± 8.1 23/30 76.7
F, Sgcem+/pGt (n=10, P16) 39.0 ± 10.4* 22/30 73.3
a
Mean total scores for abnormal movements were generated by three blinded raters.
bGenotype-phenotype matches were declared if ≥ 2/3 of the raters scored the presence of abnormal movements in Sgcem+/pGt mice or if ≤ 1/3 
scored abnormal movements in WT littermates.
*p < 0.05.
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Table 6
Genes significantly up- and down-regulated in Sgcem+/pGt mice
Affymetrix Cluster ID Gene Symbol Gene Name Fold Change ≥ 1.25 & p ≤ 0.05)
17400862 Hmgcs2 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 1.250
17522876 Eomes Eomesodermin homolog (Xenopus laevis) 1.250
17347355 Eif2ak2 Eukaryotic translation initiation factor 2-alpha kinase 2 1.255
17436237 Fosl2 FOS-like antigen 2 1.255
17301615 Gm21685 Predicted gene, 21685 1.256
17259078 Rnf213 Ring finger protein 213 1.256
17222819 9330175M20Rik RIKEN cDNA 9330175M20 gene 1.262
17300591 Irf9 Interferon regulatory factor 9 1.264
17473666 Vmn1r67 Vomeronasal 1 receptor 67 1.266
17435577 LOC102638085 1.268
17234423 Derl3 Der1-like domain family, member 3 1.274
17403237 Gbp3 Guanylate binding protein 3 1.275
17411147 Ifi44 Interferon-induced protein 44 1.284
17547813 Gm19845 Predicted gene, 19845 1.289
17350009 Gm24690 Predicted gene, 24690 1.290
17487489 Pvr Poliovirus receptor 1.293
17516383 Snord14e Small nucleolar RNA, C/D box 35A 1.303
17538425 Snora35 Small nucleolar RNA, H/ACA box 35 1.305
17292632 n-R5s54 RNA, 5S Ribosomal Pseudogene 212 1.307
17320684 Gm24647 Predicted gene, 24647 1.318
17261033 Gm22753 Predicted gene, 22753 1.327
17481504 Olfr713 Olfactory receptor 713 1.341
17226622 Cd55 CD55 antigen 1.344
17490622 Snord35a Small Nucleolar RNA, C/D Box 35A 1.359
17455903 Asb4 Ankyrin repeat and SOCS box-containing 4 1.360
17290072 Gm25985 Predicted gene, 25985 1.373
17290072 Traj13 T Cell Receptor Alpha Joining 13 1.389
17361435 Npas4 Neuronal PAS domain protein 4 1.394
17315178 Nr4a1 Nuclear receptor subfamily 4, group A, member 1 1.404
17335467 Cdkn1a Cyclin-dependent kinase inhibitor 1A (P21) 1.410
17464654 Pdk4 Pyruvate dehydrogenase kinase, isoenzyme 4 1.426
17342642 Dusp1 Dual specificity phosphatase 1 1.453
17385374 Nr4a2 Nuclear receptor subfamily 4, group A, member 2 1.494
17358658 Gm23426 Predicted gene, 23426 1.518
17277387 Fos FBJ osteosarcoma oncogene 1.698
17413945 Nr4a3 Nuclear receptor subfamily 4, group A, member 3 1.718
17308165 Gm21464 Predicted gene, 21464 1.856
17252875 1700016P03Rik RIKEN cDNA 1700016P03 gene 2.046
17464588 Sgce Sarcoglycan, epsilon −2.098
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Affymetrix Cluster ID Gene Symbol Gene Name Fold Change ≥ 1.25 & p ≤ 0.05)
17546762 Mid1 Midline 1 −1.883
17532694 Pisd-ps3 Phosphatidylserine decarboxylase, pseudogene 3 −1.805
17464803 Ica1 Islet cell autoantigen 1 −1.566
17546212 G530011O06Rik RIKEN cDNA G530011O06 gene −1.564
17403844 Gm24373 Predicted gene, 24373 −1.551
17270615 Gm22743 Predicted gene, 22743 −1.478
17491505 Gm24966 Predicted gene, 24966 −1.457
17308963 Gm23926 Predicted gene, 23926 −1.398
17278781 Gm23347 Predicted gene, 23347 −1.349
17455971 Mios Missing oocyte, meiosis regulator, homolog (Drosophila) −1.334
17491503 Gm25499 Predicted gene, 25499 −1.333
17456204 Capza2 Capping protein (actin filament) muscle Z-line, alpha 2 −1.333
17539189 Gm23806 Predicted gene, 23806 −1.330
17364365 Gm24930 Predicted gene, 24930 −1.327
17491527 Gm25870 Predicted gene, 25870 −1.318
17356739 Mir194-2 microRNA 194-2 −1.297
17283683 Gm24334 Predicted gene, 24334 −1.288
17274184 Socs2 Suppressor of cytokine signaling 2 −1.288
17432577 Gm436 Predicted gene 436 −1.287
17399769 S100a13 S100 calcium binding protein A13 −1.282
17491642 Snord107 Small Nucleolar RNA, C/D Box 107 −1.281
17363082 Olfr1437 Olfactory receptor 1437 −1.278
17440618 Mir701 microRNA 701 −1.278
17478956 Gm7551 Heterogeneous nuclear ribonucleoprotein A3 pseudogene −1.277
17460861 Slc41a3 Solute carrier family 41, member 3 −1.273
17278840 Mir376a microRNA 376a −1.271
17288946 Mir9-2 microRNA 9-2 −1.261
17491507 Gm22496 Predicted gene, 22496 −1.259
17491515 Gm25121 Predicted gene, 25121 −1.256
17284609 Ighv1-62-3 Immunoglobulin heavy variable 1-62-3 −1.254
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Table 7
Validation of whole-genome gene expression with relative quantitative RT-PCR.
Gene symbol Protein Function
Fold Change (p value) *
Microarray QRT-PCR
Nr4a3 Nuclear receptor subfamily 4 group A 
member 3
Transcriptional activator 1.72 ± 0.17 (9.0E-4) 1.93 ± 0.15 
(6.0E-5)
Nr4a2 Nuclear receptor subfamily 4 group A 
member 2
Transcriptional activator 1.49 ± 0.14 (4.0E-3) 1.29 ± 0.10 (0.010)
Dusp1 Dual specificity protein phosphatase 1 Regulation of cellular 
proliferation
1.45 ± 0.14 (3.0E-4) 2.17 ± 0.12 
(8.0e-7)
Cdkn1a Cyclin-dependent kinase inhibitor 1 Regulator of cell cycle 
progression
1.41 ±0.16 (4.0E-3) 1.50 ± 0.12 
(1,0E-3)
Eomes Eomesodermin Transcriptional activator 1.25 ± 0.06 (0.035) 1.63 ± 0.17 
(1.0E-4)
Spry4 Sprouty homolog 4 Inhibitor of mitogen-activated 
protein kinase (MAPK) signaling 
pathway
1.24 ± 0.09 (0.027) 1.21 ± 0.08 (0.018)
Slc41a3 Solute carrier family 41 member 3 Cation transmembrane transporter 
activity
−1.27 ± 0.09 (0.045) −1.42 ± 0.07 
(3.0E-4)
S100a13 S100 calcium-binding protein A13 Calcium ion binding and lipid 
binding
−1.28 ± 0.04 (1.7E-3) −1.52 ± 0.05 
(1.0E-4)
Socs2 Suppressor of cytokine signaling 2 Suppressor of cytokine signaling 
(SOCS)
−1.29 ± 0.09 (0.016) −1.29 ± 0.04 
(4.0E-4)
Capza2 F-actin-capping protein subunit alpha-2 Regulator of the actin filaments −1.33 ± 0.05 (6.0E-5) −1.18 ± 0.16 
(0.131)
Mios WD repeat-containing protein mio Inhibitor of the target of 
rapamycin complex I
−1.33 ± 0.04 (2.0E-4) −1.22 ± 0.11 
(0.049)
Ica1 Islet cell autoantigen 1 Membrane protein on Golgi 
complex and immature secretory 
granules
−1.56 ± 0.04 (6.0E-6) −1.86 ± 0.04 
(3.0E-6)
Pomt2 Protein-O-mannosyltransferase 2 Modification of the protein alpha-
dystroglycan
−1.01 ± 0.02 (0.678) 1.01 ± 0.07 (0.886)
Sgca Sarcoglycan, alpha Component of the dystrophin-
glycoprotein complex (DGC)
1.04 ± 0.02 (0.216) 1.05 ± 0.03 (0.459)
Sgcb Sarcoglycan, beta Component of DGC −1.06 ± 0.02 (0.209) −1.05 ± 0.05 
(0.308)
*
Means ± SEM (p value)
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